Latest Insider Transactions at Acutus Medical, Inc. (AFIB)
This section provides a real-time view of insider transactions for Acutus Medical, Inc. (AFIB). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Acutus Medical, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Acutus Medical, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 16
2022
|
Shaden Marzouk Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,400
+40.34%
|
-
|
|
Jun 03
2022
|
R Scott Huennekens Director |
SELL
Open market or private sale
|
Indirect |
60,000
-10.57%
|
$0
$0.58 P/Share
|
|
Jun 01
2022
|
David Roman President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
100,000
+35.29%
|
-
|
|
Apr 01
2022
|
David Roman President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,248
-3.75%
|
$3,248
$1.3 P/Share
|
|
Apr 01
2022
|
Steven Mc Quillan SVP, Clinical Affairs & QA |
SELL
Payment of exercise price or tax liability
|
Direct |
733
-1.57%
|
$733
$1.3 P/Share
|
|
Apr 01
2022
|
Vincent J Burgess Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,896
-5.96%
|
$3,896
$1.3 P/Share
|
|
Feb 01
2022
|
David Roman President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+36.6%
|
-
|
|
Feb 01
2022
|
Steven Mc Quillan SVP, Clinical Affairs & QA |
BUY
Grant, award, or other acquisition
|
Direct |
32,000
+40.72%
|
-
|
|
Nov 15
2021
|
James F. Hinrichs Director |
BUY
Open market or private purchase
|
Direct |
40,000
+43.05%
|
$120,000
$3.78 P/Share
|
|
Aug 10
2021
|
Niamh Louise Pellegrini Director |
BUY
Grant, award, or other acquisition
|
Direct |
4,172
+50.0%
|
-
|
|
Aug 05
2021
|
Vincent J Burgess Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,922
-2.86%
|
$28,830
$15.52 P/Share
|
|
Aug 05
2021
|
Steven Mc Quillan SVP, Clinical Affairs & QA |
SELL
Payment of exercise price or tax liability
|
Direct |
305
-2.05%
|
$4,575
$15.52 P/Share
|
|
Jul 19
2021
|
David P Bonita Director |
BUY
Open market or private purchase
|
Indirect |
1,071,428
+15.17%
|
$14,999,992
$14.0 P/Share
|
|
Jul 19
2021
|
Orbimed Advisors LLC Director |
BUY
Open market or private purchase
|
Indirect |
1,071,428
+15.17%
|
$14,999,992
$14.0 P/Share
|
|
Jul 19
2021
|
James E Flynn Director |
BUY
Open market or private purchase
|
Indirect |
1,071,428
+16.52%
|
$14,999,992
$14.0 P/Share
|
|
Jun 17
2021
|
James E Flynn Director |
BUY
Grant, award, or other acquisition
|
Indirect |
1,800
+30.92%
|
-
|
|
Jun 17
2021
|
David P Bonita Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,800
+30.92%
|
-
|
|
Jun 17
2021
|
Andrew El Bardissi Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,800
+30.92%
|
-
|
|
Jun 17
2021
|
Shahzad Malik Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,800
+30.92%
|
-
|
|
Jun 17
2021
|
Shaden Marzouk Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,800
+30.92%
|
-
|
|
Jun 17
2021
|
James F. Hinrichs Director |
BUY
Grant, award, or other acquisition
|
Direct |
1,800
+12.24%
|
-
|
|
Apr 01
2021
|
Vincent J Burgess Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
45,065
+40.11%
|
-
|
|
Apr 01
2021
|
Steven Mc Quillan SVP, Clinical Affairs & QA |
BUY
Grant, award, or other acquisition
|
Direct |
9,882
+39.9%
|
-
|
|
Apr 01
2021
|
David Roman President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
36,603
+50.0%
|
-
|
|
Mar 17
2021
|
John F Sheridan Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,147
+29.43%
|
-
|
|
Feb 03
2021
|
Daniella Cramp Director |
BUY
Grant, award, or other acquisition
|
Direct |
2,423
+42.92%
|
-
|
|
Aug 10
2020
|
Orbimed Advisors LLC Director |
BUY
Conversion of derivative security
|
Indirect |
5,062,958
+48.43%
|
-
|
|
Aug 10
2020
|
Orbimed Advisors LLC Director |
BUY
Open market or private purchase
|
Indirect |
415,000
+50.0%
|
$7,470,000
$18.0 P/Share
|
|
Aug 10
2020
|
James E Flynn Director |
BUY
Open market or private purchase
|
Indirect |
1,500,000
+27.06%
|
$27,000,000
$18.0 P/Share
|
|
Aug 10
2020
|
James E Flynn Director |
BUY
Conversion of derivative security
|
Indirect |
2,841,802
+38.53%
|
-
|
|
Aug 05
2020
|
James E Flynn Director |
BUY
Grant, award, or other acquisition
|
Indirect |
2,222
+50.0%
|
-
|